Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges

References

• Ferlay J , ColombetM, SoerjomataramIet al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer144, 1941–1953 (2019).
   PubMed Web of Science ®Google Scholar
• Wang S , SunX, SunHet al. Survival improvement in patients with non-small cell lung cancer between 1983 and 2012: analysis of the Surveillance, Epidemiology, and End Results database. Tumour Biol.39(5), 1010428317691677 (2017).
   Google Scholar
• Lu T , YangX, HuangYet al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag. Res.11, 943–953 (2019).
   PubMed Web of Science ®Google Scholar
• Howlader N , ForjazG, MooradianMJet al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med.383(7), 640–649 (2020).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG , JännePA, LeeJCet al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Reck M , RabeKF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N. Engl. J. Med.377(9), 849–861 (2017).
   PubMed Web of Science ®Google Scholar
• Mielgo-Rubio X , AzkonaE, QuintanaL, SerenoM. Immunotherapy in non-small cell lung cancer: update and new insights. J. Clin. Transl. Res.7(1), 1 (2021).
   PubMedGoogle Scholar
• Goldstraw P , ChanskyK, CrowleyJet al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol.11(1), 39–51 (2016).
   PubMed Web of Science ®Google Scholar
• Pignon JP , TribodetH, ScagliottiGVet al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol.26(21), 3552–3559 (2008).
   PubMed Web of Science ®Google Scholar
• Wakelee HA , DahlbergSE, KellerSMet al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol.18(12), 1610–1623 (2017).
   PubMed Web of Science ®Google Scholar
• Le Pechoux C , PourelN, BarlesiFet al. LBA3_PR an international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann. Oncol.31, S1178 (2020).
   PubMed Web of Science ®Google Scholar
• Antonia J , VillegasA, DanielDet al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med.379, 2342–2350 (2018).
   PubMed Web of Science ®Google Scholar
• Hoang T , MyungSK, PhamTT, KimJ, JuW. Comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials. J. Clin. Med.9(4), 1063 (2020).
   PubMed Web of Science ®Google Scholar
• Kneuertz PJ , CarboneDP, D'SouzaDMet al. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma. Lung Cancer143, 60–66 (2020).
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Lung Cancer . Staging and Prognostic Factors Committee (2020). https://www.iaslc.org/research-education/research-committees-projects/staging-and-prognostic-factors-committee
   Google Scholar
• Donoghue MTA , SchramAM, HymanDM, TaylorBS. Discovery through clinical sequencing in oncology. Nat. Cancer1(8), 774–783 (2020).
   PubMedGoogle Scholar
• Kim L , TsaoMS. Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?Eur. Resp. J.44, 1011–1022 (2014).
   PubMed Web of Science ®Google Scholar
• Han Y , LiJ. Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine. Clin. Chem. Lab. Med.55(12), 1817–1833 (2017).
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ311(7010), 899–909 (1995).
   PubMedGoogle Scholar
• Arriagada R , BergmanB, DunantAet al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med.350(4), 351–360 (2004).
   PubMed Web of Science ®Google Scholar
• Arriagada R , DunantA, PignonJPet al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J. Clin. Oncol.28(1), 35–42 (2009).
   PubMed Web of Science ®Google Scholar
• Kelly K , AltorkiNK, EberhardtWEet al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J. Clin. Oncol.33(34), 4007–4014 (2015).
   PubMed Web of Science ®Google Scholar
• Goss GD , O'CallaghanC, LorimerIet al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J. Clin. Oncol.31(27), 3320–3326 (2013).
   PubMed Web of Science ®Google Scholar
• Wu Y , ZhongW, WangQet al. CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation – final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. J. Clin. Oncol.38(15), 9005 (2020).
   Google Scholar
• Yue D , XuS, WangQet al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Resp. Med.6(11), 863–873 (2018).
   PubMed Web of Science ®Google Scholar
• Wu Y , TsuboiM, HeJet al. Osimertinib in resected EGFR-mutated non-cell lung cancer. N. Engl. J. Med.383(18), 1711–1723 (2020).
   PubMed Web of Science ®Google Scholar
• Suda K . For a better adjuvant strategy for resected lung cancer-lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104). Trans. Lung Cancer Res.8(4), S395–S399 (2019).
   PubMedGoogle Scholar
• Adeo A , BannaGL, FriedlaenderA. ADAURA: mature enough for publication, not for prime time. Oncologist26, 266–268 (2021).
   PubMed Web of Science ®Google Scholar
• West HJ , GyawaliB. Why not adore ADAURA? The trial we need vs the trial we got. JAMA Oncol.7(5), 677–678 (2021).
   PubMed Web of Science ®Google Scholar
• Gyawali B , WestHJ. Lessons from ADAURA on adjuvant cancer drug trials: evidence, ethics, and economics. J. Clin. Oncol.39(3), 175–177 (2021).
   PubMed Web of Science ®Google Scholar
• Govindan R , MandrekarSJ, GerberDEet al. ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer. Clin. Cancer Res.21(24), 5439–5444 (2015).
   PubMed Web of Science ®Google Scholar
• He J , LiangW, XuSet al. Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: a multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501). J. Clin. Oncol.34(15), TPS8570 (2016).
   Google Scholar
• Zhong W , YangX, YanHet al. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J. Hematol. Oncol.8, 54 (2015).
   PubMed Web of Science ®Google Scholar
• Xiong L , LiR, SunJet al. Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm, phase II study. Oncologist24(2), 157-e64 (2019).
   PubMed Web of Science ®Google Scholar
• Xiong L , LouY, BaiHet al. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. J. Int. Med. Res.48(4), 300060519887275 (2019).
   PubMedGoogle Scholar
• Sequist LV , WillersH, LanutiMet al. The ASCENT trial: a phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC. J. Clin. Oncol.36(15), 8544 (2018).
   Web of Science ®Google Scholar
• Addeo A , TabbòF, RobinsonT, BuffoniL, NovelloS. Precision medicine in ALK rearranged NSCLC: a rapidly evolving scenario. Crit. Rev. Oncol. Hematol.122, 150–156 (2018).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , AhnJS, BarlesiFet al. ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). J. Clin. Oncol.37(15), TPS8569 (2019).
   Web of Science ®Google Scholar
• Chinnaiyan P , HuangS, VallabhaneniGet al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res.65(8), 3328–3335 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich RK , MikkelsenRB, DentPet al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene15(10), 1191–1197 (1997).
   PubMed Web of Science ®Google Scholar
• Zhuang H , BoQ, YuanZ, WangJ, ZhaoL, WangP. The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction. Onco Targets Ther.6, 603–608 (2013).
   PubMed Web of Science ®Google Scholar
• Sun J , LiuNB, ZhuangHQ, ZhaoLJ, YuanZY, WangP. Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell. Cancer Biomark.19(1), 45–50 (2017).
   PubMed Web of Science ®Google Scholar
• Dai Y , WeiQ, SchwagerCet al. Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer. Radiother. Oncol.114(2), 173–181 (2015).
   PubMed Web of Science ®Google Scholar
• Couñago F , RodríguezA, CalvoPet al. Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clin. Transl. Oncol.19(1), 31–43 (2017).
   PubMed Web of Science ®Google Scholar
• Bitterman DS , DuKL. Safety and efficacy of combination targeted therapy and radiotherapy. Am. J. Hematol. Oncol.12(1), 23–31 (2016).
   Google Scholar
• Kroeze SGC , FritzC, HoyerMet al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat. Rev.53, 25–37 (2017).
   PubMed Web of Science ®Google Scholar
• Kroeze SGC , FritzC, BaslerLet al. Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. Strahlenther. Onkol.195(3), 199–206 (2019).
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr , PaulusR, CurranWJet al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J. Clin. Oncol.29(17), 2312–2318 (2011).
   PubMed Web of Science ®Google Scholar
• Govindan R , BogartJ, StinchcombeTet al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and Leukemia Group B trial 30407. J. Clin. Oncol.29(23), 3120–3125 (2011).
   PubMed Web of Science ®Google Scholar
• van den Heuvel MM , UyterlindeW, VincentADet al. Additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiother. Oncol.110(1), 126–131 (2014).
   PubMed Web of Science ®Google Scholar
• Bradley JD , HuC, KomakiRRet al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 38(7), 706–714 (2020).
   PubMed Web of Science ®Google Scholar
• Edelman MJ , HuC, LeQTet al. Randomized phase II study of preoperative chemoradiotherapy ± panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer: NRG Oncology RTOG 0839. J. Thorac. Oncol.12(9), 1413–1420 (2017).
   PubMed Web of Science ®Google Scholar
• Zhuang H , YuanZ, ChangJYet al. Radiation pneumonitis in patients with non–small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J. Thorac. Oncol.9(6), 882–885 (2014).
   PubMed Web of Science ®Google Scholar
• Xu K , LiangJ, ZhangTet al. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. Thorac Cancer. 12, 814–823 (2021).
   PubMed Web of Science ®Google Scholar
• Martínez E , MartínezM, RicoMet al. Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a phase II trial. Onco Targets Ther.9, 1057–1066 (2016).
   PubMed Web of Science ®Google Scholar
• Zheng L , WangY, XuZet al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist24(8), 1031-e612 (2019).
   PubMed Web of Science ®Google Scholar
• Kelly K , ChanskyK, GasparLEet al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol.26(15), 2450–2456 (2008).
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE , MorrisDE, LeeCBet al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J. Thorac. Oncol.3(3), 250–257 (2008).
   PubMed Web of Science ®Google Scholar
• Choong NW , MauerAM, HarafDJet al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J. Thorac. Oncol.3(9), 1003–1011 (2008).
   PubMed Web of Science ®Google Scholar
• Center B , PettyWJ, AyalaDet al. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J. Thorac. Oncol.5(1), 69–74 (2010).
   PubMed Web of Science ®Google Scholar
• Ready N , JännePA, BogartJet al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J. Thorac. Oncol.5(9), 1382–1390 (2010).
   PubMed Web of Science ®Google Scholar
• Okamoto I , TakahashiT, OkamotoHet al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer72(2), 199–204 (2011).
   PubMed Web of Science ®Google Scholar
• Rothschild S , BucherSE, BernierJet al. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. Int. J. Radiat. Oncol. Biol. Phys.80(1), 126–132 (2011).
   PubMed Web of Science ®Google Scholar
• Ball D , BurmeisterB, MitchellPet al. P2-162: phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non small cell lung cancer (“CRITICAL”). J. Thorac. Oncol.2(8), S633–S634 (2007).
   Web of Science ®Google Scholar
• Niho S , OheY, IshikuraSet al. Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Ann Oncol. 23(9), 2253–2258 (2012).
   PubMed Web of Science ®Google Scholar
• Ramella S , AlbertiAM, CammilluzziEet al. Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results. BioMed Res. Int.2013, 403869 (2013).
   PubMed Web of Science ®Google Scholar
• Pennell NA , NealJW, ChaftJEet al. SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J. Clin. Oncol.37(2), 97–104 (2019).
   PubMed Web of Science ®Google Scholar
• Joensuu H , ErikssonM, HallKSet al. Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up. JAMA Oncol.6(8), 1241–1246 (2020).
   PubMed Web of Science ®Google Scholar
• Chaft JE , CostaDB, MuzikanskyAet al. Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. J. Clin. Oncol.37(15), 8507 (2019).
   Web of Science ®Google Scholar
• Sands J , MandrekarSJ, OxnardGRet al. ALCHEMIST: adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. J. Clin. Oncol.38(15), TPS9077 (2020).
   Web of Science ®Google Scholar
• Kim C , LiuSV. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Ann. Oncol.30(12), 1852–1855 (2019).
   PubMed Web of Science ®Google Scholar
• Lee C , KimS, LeeJSet al. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer113, 106–114 (2017).
   PubMed Web of Science ®Google Scholar
• Chaft JE , OxnardGR, SimaCS, KrisMG, MillerVA, RielyGJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res.17(19), 6298–6303 (2011).
   PubMed Web of Science ®Google Scholar
• Kuriyama Y , KimYH, NagaiH, OzasaH, SakamoriY, MishimaM. Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer. Case Rep. Oncol.6(2), 430–433 (2013).
   PubMedGoogle Scholar
• Chaudhuri AA , ChabonJJ, LovejoyAFet al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov.7(12), 1394–1403 (2017).
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I , BrannonAR, FerrisLAet al. Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO Precis. Oncol.2018, PO.17.00160 (2018).
   PubMedGoogle Scholar
• Chabon JJ , SimmonsAD, LovejoyAFet al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun.7, 11815 (2016).
   PubMed Web of Science ®Google Scholar
• Russo A , LopesAR, McCuskerMGet al. New targets in lung cancer (excluding EGFR, ALK, ROS1). Curr. Oncol. Rep.22(5), 48 (2020).
   PubMed Web of Science ®Google Scholar